Monograph Details
|
|
Dermatological Disorders
> Acne
|
|
TAZORAC |
| Manufacturer |
|
Allergan |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Retinoid. |
| Generic Name |
|
Tazarotene 0.05%, 0.1%; gel; crm. |
| Indications |
|
Mild to moderate facial acne vulgaris (0.1% strength only). |
| Children |
|
Not recommended. |
| Adults |
|
Cleanse and dry skin. Apply thin film of 0.1% strength to lesions on face once daily in the PM. Women of childbearing potential: begin therapy during normal menses. |
| Contraindications |
|
Pregnancy (Cat.X). |
| Precautions |
|
Obtain reliable negative pregnancy test within 2 weeks before starting therapy; use effective contraception during therapy. Do not use on broken, eczematous, or sunburned skin. Sun sensitivity. Avoid eyes, eyelids, mouth, sun and UV light; use adequate sun protection. Increased irritation in extreme weather. Discontinue if excessive irritation occurs. Nursing mothers. |
| Interactions |
|
Avoid use until the effects of strong topical drying agents have subsided. Caution with other photosensitizers or irritants. |
| Adverse Reactions |
|
Desquamation, burning/stinging, dry skin, erythema, pruritus, other local reactions. |
| How Supplied |
Gel—30g, 100g
Cream—15g, 30g, 60g |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
